RxDoctor Payments Data

Vincent Spagnuolo Jr, MD

Cardiovascular Disease · Moorestown, NJNPI 1487621090

Payments from drug & device makers

$3,127in general payments, 2019–2025

Across 197 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$629
  • Amgen$524
  • Novartis$295
  • Johnson & Johnson$221
  • Pfizer$210
  • Sanofi-aventis U.S. LLC$194
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,127100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,127 in reported general payments places this provider in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$200,551
Medicare patients
690
Services billed
2,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban589$706,601
XareltoRivaroxaban191$231,411
EntrestoSacubitril/Valsartan137$158,362
Repatha SureclickEvolocumab95$97,174
Praluent PenAlirocumab49$57,117
FarxigaDapagliflozin Propanediol43$50,651
JardianceEmpagliflozin29$44,930
Carvedilol ErCarvedilol Phosphate27$17,918
BrilintaTicagrelor16$15,808
DapagliflozinDapagliflozin Propanediol14$8,453
Atorvastatin Calcium688$8,174
Metoprolol Succinate469$7,401
Rosuvastatin Calcium476$6,536
Ezetimibe205$5,746
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$706,601589 claims
Johnson & JohnsonXarelto$221$231,411191 claims
NovartisEntresto$295$158,362137 claims
AstraZenecaFarxiga, Brilinta$37$66,45959 claims
Boehringer IngelheimJardiance$100$44,93029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →